NASDAQ:HSICHenry Schein Stock Price, Forecast & News

Henry Schein's stock was trading at $57.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HSIC stock has decreased by 19.6% and is now trading at $46.35. View which stocks have been mosted impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Henry Schein.

Henry Schein is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Henry Schein.

Henry Schein, Inc. (NASDAQ:HSIC) released its quarterly earnings results on Thursday, February, 20th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.91 by $0.06. The firm had revenue of $2.67 billion for the quarter, compared to analyst estimates of $2.64 billion. Henry Schein had a net margin of 6.96% and a return on equity of 15.01%. The firm's revenue was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.12 EPS. View Henry Schein's earnings history.

Henry Schein's stock split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were issued to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein announced that its Board of Directors has approved a stock repurchase program on Thursday, October 31st 2019, which permits the company to repurchase $400,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy up to 4.3% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's management believes its stock is undervalued.

Henry Schein updated its FY20 earnings guidance on Thursday, February, 20th. The company provided EPS guidance of $3.65 to $3.75 for the period, compared to the Thomson Reuters consensus estimate of $3.70.

13 analysts have issued 12-month price targets for Henry Schein's stock. Their forecasts range from $57.00 to $80.00. On average, they expect Henry Schein's stock price to reach $70.22 in the next twelve months. This suggests a possible upside of 51.5% from the stock's current price. View analysts' price targets for Henry Schein.

Headlines about HSIC stock have been trending very negative recently, InfoTrie reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Henry Schein earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutHenry Schein.

Henry Schein saw a decrease in short interest in March. As of March 13th, there was short interest totaling 14,347,300 shares, a decrease of 10.9% from the February 27th total of 16,100,000 shares. Based on an average daily trading volume, of 2,173,700 shares, the days-to-cover ratio is currently 6.6 days. Currently, 10.2% of the company's shares are short sold. View Henry Schein's Current Options Chain.

Some companies that are related to Henry Schein include McKesson (MCK), AmerisourceBergen (ABC), Cardinal Health (CAH), Patterson Companies (PDCO) and Owens & Minor (OMI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), AbbVie (ABBV), Boeing (BA), salesforce.com (CRM), UnitedHealth Group (UNH), Amgen (AMGN) and Pfizer (PFE).

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein's stock is owned by many different retail and institutional investors. Top institutional investors include M&R Capital Management Inc. (0.01%) and Neville Rodie & Shaw Inc. (0.01%). Company insiders that own Henry Schein stock include David Mckinley, E Dianne Rekow, Gerald A Benjamin, James P Breslawski, Mark E Mlotek, Michael S Ettinger, Paul Brons, Philip A Laskawy, Stanley M Bergman, Steven Paladino and Walter Siegel. View institutional ownership trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Neville Rodie & Shaw Inc., and M&R Capital Management Inc.. Company insiders that have sold Henry Schein company stock in the last year include E Dianne Rekow, Gerald A Benjamin, James P Breslawski, Michael S Ettinger, Paul Brons, Stanley M Bergman, Steven Paladino, and Walter Siegel. View insider buying and selling activity for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $46.35.

Henry Schein has a market capitalization of $6.65 billion and generates $9.99 billion in revenue each year. The company earns $694.73 million in net income (profit) each year or $3.51 on an earnings per share basis. Henry Schein employs 19,000 workers across the globe. View additional information about Henry Schein.

The official website for Henry Schein is http://www.henryschein.com/.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]